NCT06849492 (SHIFT-001) is a Phase 2 clinical trial of Camrelizumab in Advanced Triple Negative Breast Cancer, sponsored by Fudan University.

Who is sponsoring NCT06849492?

NCT06849492 is sponsored by Fudan University.

What drugs are being tested in NCT06849492?

Interventions in NCT06849492: Camrelizumab, Nab-paclitaxel, SKB264, Lenvatinib.

What condition does NCT06849492 study?

NCT06849492 studies Advanced Triple Negative Breast Cancer.

Is NCT06849492 still recruiting?

NCT06849492 is currently not yet recruiting. Last updated 27 February 2025.

Last reviewed 2025-02-27 · How we verify

NCT06849492: SHIFT-001

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer

Not yet recruiting Phase 2 Last updated 27 February 2025

What this trial tests

Phase 2 trial testing Camrelizumab in Advanced Triple Negative Breast Cancer in 120 participants. Not yet recruiting.

Timeline

1 April 2025

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	120
Start date	1 April 2025
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	1 location across China

Drugs / interventions tested

Camrelizumab — full drug profile →
Nab-paclitaxel (nab-paclitaxel) — full drug profile →
SKB264 — full drug profile →
Lenvatinib (LENVATINIB) — full drug profile →

Conditions studied

Advanced Triple Negative Breast Cancer — all drugs for Advanced Triple Negative Breast Cancer →

Sponsor

Fudan University

Who can join

18 and older, any sex, with Advanced Triple Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the efficacy and safety of treatment for recurrent and metastatic advanced first-line triple-negative breast cancer guided by cell surface protein-based subtyping (HIM).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cytokine Networks in Triple-Negative Breast Cancer: Mechanisms, Therapeutic Targets, and Emerging Strategies.
Rosado-Sanz M, Martínez-Alarcón N, Abellán-Soriano A, Golfe R, et al · · 2025 · cited 2× · PMID 40868199 · DOI 10.3390/biomedicines13081945

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Advanced Triple Negative Breast Cancer

Currently open trials in the same condition.

NCT05019690 — Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer · Phase 1, PHASE2 · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06849492 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 27 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06849492.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing